Abstract library

38 results for "Galli".
#728 NETworking-The First Three Years of the World NET Cancer Awareness Day Alliance
Introduction: Neuroendocrine tumors have an incidence of 3-5/100,000 per year, however, many patients are diagonosed late in their clinical course resulting in poor outcomes and early death. Raising awareness of the myriad presenting symptoms with resultant early diagnosis is a priority health care initiative for this disease. In 2010, the World NET Cancer Day Awareness (WNCAD) Alliance was formed with the primary mission to raise awareness of neuroendocrine tumors and promote November 10 as World NET Cancer Awareness Day
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr John C Leyden
#225 New Imaging Modalities in the Diagnosis of Phaeochromocytoma
Introduction: Phaechromocytoma are uncommon chromaffin cell tumors of the adrenal medulla. The diagnostic assessment includes various radiological localizing techniques, including somatostatin based scintigraphy.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Richard W Carroll
Authors: Amin A, Carroll R, Win Z, Palazzo F, ...
#761 Use of Molecular Imaging to Differentiate Neuroendocrine Tumors from Other Synchronous Primary Cancers: A Case Series
Introduction: Approximately 22% of neuroendocrine tumors (NET) co-exist with other cancers.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: DR Vincent Cheung
Keywords: NET, synchronous, PET, Gallium, FDG
#1292 The Role of 68Ga- DOTA-NOC PET in Evaluating Neuroendocrine Tumors: Real-World Experience from Single Lebanese Institution.
Introduction: Functional imaging with somatostatin analogues have been commonly used in NETs
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Rita Assi
Keywords: NET, Gallium PET
#2083 Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study
Introduction: Predicting treatment response at an early stage in the treatment algorithm for NET is highly desirable.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Associate prof, Magnus Kjellman
#444 Gallium 68 DOTATATE PET CT Assessment of Patients (pts.) with Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs): First Experience in a Multidisciplinary Team in Argentina (Argentum Group)
Introduction: 68Ga-DOTATATE PET CT offers higher resolution than other scintigraphic techniques in terms of localization of the primary tumor and staging of GEP NETs. Different reports in the literature suggest increased sensitivity but clear consensus about indication in neuroendocrine tumors is unclear.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Juan O'Connor
Authors: Eleta M, Pesce V, Bestani C, O'Connor J, ...
#1208 Multidisciplinary Team (MDT) in Neuroendocrine Tumor (NET) Management: Results from the First Global NET Patient (pt) Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Guidelines support an MDT approach to NETs. We present data on the global NET pt perspective regarding MDT care.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Kjell Öberg
#1217 The Neuroendocrine Tumor (NET) Patient (pt) Perspective: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Despite a rising incidence of NETs, few studies document the NET pt experience. We present data on quality of life (QoL) and the global NET pt perspective.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Dr John Leyden
Keywords: Quality of life
#1220 Time to Diagnosis of Neuroendocrine Tumors (NETs): Results from the First Global NET Patient (pt) Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Diagnosis of NETs often occurs late in the disease course, which may have an impact on pt survival. We present pt-reported data on time to diagnosis in global NET pts.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Marianne Pavel
Keywords: Diagnosis
#1231 Neuroendocrine Tumor (NET) Patient (pt) Experience and Disease Burden: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Global data on impact of NETs on pts’ lives, including differences by disease location, are poorly described. We present global data on pt experience and disease burden by NET type.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Philippe Ruszniewski
Keywords: Symptom burden
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.